INO: VOCERYQ’s FDA approval launches commercialization, backed by new financing and runway into late 2027

Inovio Pharmaceuticals (INO) discussed its plans for Voceric, including U.S. commercialization and seeking ex-U.S. partnerships. The company expects to submit a European filing by year-end 2026. FDA approval is seen as a validation for other pipeline programs. Inovio raised $80.5M in an equity offering, extending its cash runway into late 2027. Q3 2026 net loss was $49.2M, driven by non-cash warrant liability adjustments. Voceric's efficacy and safety data supported its FDA approval.

Inovio Pharmaceuticals (INO) raised $80.5M in net proceeds and $10.9M from warrant exercises, extending its cash runway to late 2027. The company's FDA-approved VOCERYQ is expected to launch in early 2027. Inovio also presented nonclinical data on next-gen programs and is seeking partners for Hemophilia A, Fabry disease, and hypophosphatasia candidates. Additionally, INO and Akeso are evaluating INO-5412 in a Phase 2 trial for glioblastoma.

Inovio (INO) reported Q3 2026 earnings, highlighting the FDA's accelerated approval of VOCERYQ for treating RRP in adults. The company raised $80.5M in an equity offering, extending its cash runway into late 2027. VOCERYQ showed significant reduction in surgeries for RRP patients in clinical trials, with a favorable safety profile. Inovio plans to focus on the commercial launch of VOCERYQ and expand its indications, while also advancing its pipeline through partnerships.

Inovio Pharmaceuticals reported a Q3 net loss of $49.2M, wider than last year. The company discussed FDA requirements for its RRP treatment, including a confirmatory study. Inovio plans to submit a draft protocol by year-end and aims for FDA agreement by mid-2027. The company estimates 25,000 U.S. patients with RRP and expects 80% insurer coverage within nine months of approval. Inovio has $48.4M in cash and expects funds to last into late Q4 2027.

Inovio Pharmaceuticals (INO) reported a late Q4 2027 cash runway during its Q3 2026 earnings call. The company aims to launch VOCERYQ and file for approval in Europe by year-end 2026, following recent FDA approval under the Accelerated Approval Program.

Inovio Pharmaceuticals reported a Q3 2026 net loss of $49.2M, wider than expected, despite FDA approval of VOCERYQ. Shares fell 3.97% to $1.45, then another 10.34% after hours. Operating expenses declined 7% YoY, but non-cash losses increased. Cash reserves total $48.4M, with a runway into late 2027. VOCERYQ targets recurrent respiratory papillomatosis, showing 50-100% surgery reduction in trials. The company plans a Q1 2027 launch and European filings by year-end.